XBIvsETF 2ETF Comparison
VS
Choose a second ETF to run a side-by-side ETF comparison with XBI, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
XBI performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 09/04/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | XBI ETF 2 | +7.89%– | +22.96%– | +34.48%– | +76.10%– | +107.25%– | +23.60%– |
| Flows | XBI ETF 2 | +$725M– | +$1.19B– | +$925M– | +$1.79B– | +$130M– | +$1.57B– |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | XBI ETF 2 | +30.41%– | +27.90%– | +28.23%– | +32.90%– |
| Max drawdown | XBI ETF 2 | -10.46%– | -10.46%– | -32.94%– | -53.28%– |
| Max drawdown duration | XBI ETF 2 | 40d– | 40d– | 331d– | 1622d– |
Trading data
XBI | ETF 2 | |
Last sale 9/9/2026 at 2:24 PM | $160.85 | – |
| Previous close 09/04/2026 | $161.93 | – |
| Consolidated volume 09/04/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of August 31, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
XBI | ETF 2 | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 9/9/2026 at 2:24 PM
Live
Closed
XBI | ETF 2 | |
|---|---|---|
| Last price | $160.85 | – |
| 1D performance | -0.67% | – |
| AuM | $11.43 B | – |
| E/R | 0.35% | – |
Characteristics
XBI | ETF 2 | |
|---|---|---|
| Management strategy | Passive | – |
| Provider | State Street Investment Management | – |
| Benchmark | S&P Biotechnology Select Industry Index | – |
| N° of holdings | 149 | – |
| Asset class | Equities | – |
| Trailing 12m distribution yield | Join | Join |
| Inception date | January 31, 2006 | – |
| ESG | No | – |
Advertisement
Exposure
Countries
XBI
USA
95.3%
Other
4.7%
ETF 2
Sectors
XBI
Healthcare
99.41%
Other
0.59%
ETF 2
Advertisement
Diversification
XBI
Total weight of top 15 holdings out of 15
20.29%
ETF 2
–
Top 15 holdings
Data as of July 31, 2026
XBI
Apogee Therapeutics, Inc.
1.65%
Oruka Therapeutics, Inc.
1.53%
Dianthus Therapeutics, Inc.
1.42%
Erasca, Inc.
1.38%
Twist Bioscience Corp.
1.37%
Kymera Therapeutics, Inc.
1.34%
Spyre Therapeutics, Inc.
1.33%
Revolution Medicines, Inc.
1.32%
CG Oncology, Inc.
1.32%
Protagonist Therapeutics, Inc.
1.31%
Praxis Precision Medicines, Inc.
1.30%
Regeneron Pharmaceuticals, Inc.
1.29%
Cogent Biosciences, Inc.
1.26%
Natera, Inc.
1.26%
Arrowhead Pharmaceuticals, Inc.
1.22%
ETF 2
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
Advertisement
Latest news about XBI
Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities
September 18, 2025
XBI
Are Biotechnology ETFs In the Midst of a Comeback?
August 20, 2025
XBI
Two biotech ETFs to watch for the rest of 2022 and beyond
September 13, 2022
XBI
Biotech ETFs – Investing in Health Innovation
July 21, 2022
XBI
Advertisement
Advertisement
